ATE372348T1 - Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung - Google Patents

Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung

Info

Publication number
ATE372348T1
ATE372348T1 AT03729265T AT03729265T ATE372348T1 AT E372348 T1 ATE372348 T1 AT E372348T1 AT 03729265 T AT03729265 T AT 03729265T AT 03729265 T AT03729265 T AT 03729265T AT E372348 T1 ATE372348 T1 AT E372348T1
Authority
AT
Austria
Prior art keywords
clever
endothelial
receptor
vascular
vascular endothelial
Prior art date
Application number
AT03729265T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Heikki Irjala
Marko Salmi
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ATE372348T1 publication Critical patent/ATE372348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03729265T 2002-01-09 2003-01-08 Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung ATE372348T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34628802P 2002-01-09 2002-01-09

Publications (1)

Publication Number Publication Date
ATE372348T1 true ATE372348T1 (de) 2007-09-15

Family

ID=23358731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729265T ATE372348T1 (de) 2002-01-09 2003-01-08 Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung

Country Status (9)

Country Link
US (2) US7354577B2 (de)
EP (1) EP1463760B1 (de)
JP (1) JP4387797B2 (de)
AT (1) ATE372348T1 (de)
AU (1) AU2003201168A1 (de)
CA (1) CA2468888C (de)
DE (1) DE60316106T2 (de)
ES (1) ES2289293T3 (de)
WO (1) WO2003057130A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468888C (en) * 2002-01-09 2013-03-12 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
FI20090161A0 (fi) * 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
WO2017182706A1 (en) 2016-04-18 2017-10-26 Faron Pharmaceuticals Oy Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents
PT3445785T (pt) * 2016-04-18 2022-09-21 Faron Pharmaceuticals Oy Anticorpos anti clever-1 humanizados e sua utilização
US20210261657A1 (en) 2018-06-21 2021-08-26 Faron Pharmaceuticals Oy Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitor
AU2019370785A1 (en) 2018-11-01 2021-04-22 Faron Pharmaceuticals Oy TLR9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
CN110452871A (zh) * 2019-08-28 2019-11-15 遵义医学院附属医院 一种淋巴液净化模型制作方法
US20220357348A1 (en) 2019-09-24 2022-11-10 Faron Pharmaceuticals Oy Method for determining potency of therapeutic anti-clever-1 antibody
US20220404366A1 (en) 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
WO2021100891A1 (ko) * 2019-11-19 2021-05-27 경상대학교병원 구강암 예후 진단용 조성물 및 키트
EP4139351A1 (de) 2020-04-20 2023-03-01 Faron Pharmaceuticals OY Behandlung von krankheiten mit clever-1-hemmung in kombination mit einem interleukinhemmer
FI129383B (en) 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment
WO2023222953A1 (en) 2022-05-20 2023-11-23 Faron Pharmaceuticals Oy Method for identifying cancer patients that benefit from anti-clever-1 treatment
WO2023222952A1 (en) 2022-05-20 2023-11-23 Faron Pharmaceuticals Oy Method for identifying cancer patients that benefit from anti-clever-1 treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5821340A (en) 1989-02-14 1998-10-13 Brigham & Women's Hospital Inducible endothelial surface protein mediating lymphoid and tumor cell adhesion: antibodies and uses
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
JPH1134127A (ja) * 1997-07-16 1999-02-09 Toshiba Mach Co Ltd 射出成形機の射出装置
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
AU2057800A (en) 1998-12-23 2000-07-31 American Red Cross Novel hyaluronan-binding proteins and encoding genes
IL133647A0 (en) * 1999-06-08 2001-04-30 Yissum Res Dev Co Novel cd44 variant
CA2468888C (en) * 2002-01-09 2013-03-12 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof

Also Published As

Publication number Publication date
US7910097B2 (en) 2011-03-22
US20050069888A1 (en) 2005-03-31
JP2005523247A (ja) 2005-08-04
AU2003201168A1 (en) 2003-07-24
WO2003057130A2 (en) 2003-07-17
CA2468888C (en) 2013-03-12
DE60316106D1 (de) 2007-10-18
AU2003201168A8 (en) 2003-07-24
CA2468888A1 (en) 2003-07-17
US20080267958A1 (en) 2008-10-30
JP4387797B2 (ja) 2009-12-24
EP1463760A2 (de) 2004-10-06
WO2003057130A3 (en) 2003-09-18
DE60316106T2 (de) 2008-05-29
US7354577B2 (en) 2008-04-08
EP1463760B1 (de) 2007-09-05
ES2289293T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
ATE372348T1 (de) Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
ATE420861T1 (de) 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
ATE325096T1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE69717268T2 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
ATE269327T1 (de) Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
DK1617832T3 (da) Præparater til påvirkning af vægttab
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DE69831013D1 (de) Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
DE60326077D1 (de) Substituierte 4-(indazol-3-yl)phenole als liganden des oestrogenrezeptors und deren verwendung bei der behandlung von entzündlichen erkrankungen
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
DE69819311D1 (de) Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
NO20032254L (no) Forbindelser for inhibering av ekspresjon av VACM-I
ATE292615T1 (de) Inhibitoren der durch alpha 4 vermittelten zelladhäsion
TR200402535T4 (tr) Serin proteaz inhibitörleri.
DE60206616D1 (de) Trizyclische alkylhydroxamate, ihre herstellung und ihre verwendung als inhibitoren der zellproliferation
CY1106573T1 (el) Ανοσοθεραπεια καρκινου
NO974943D0 (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
TR200705187T1 (tr) 2-Kromen hazırlanması için yeni yöntemler
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
DE60129572D1 (de) Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
ATE303989T1 (de) Inhibitoren von serin proteasen
ATE385796T1 (de) N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
ATE131071T1 (de) Leukozyten-adhäsions-inhibitor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties